Targeted therapies for breast cancer are evolving rapidly. Trastuzumab has revolutionized breast cancer treatment and outcome, reducing the risk for recurrence and significantly increasing survival, at least for a subgroup of patients. Other targeted therapies, such as bevacizumab, a monoclonal antibody targeting angiogenesis, lapatinib, a dual human epidermal growth factor receptor (HER)-1 and HER-2 inhibitor, other small-molecule tyrosine kinase inhibitors, and mammalian target of rapamycin inhibitors, have been developed in phase II and III clinical trials. Although there has been rapid approval of these new drugs by health authorities, some questions have emerged about their application in clinical practice. What is the appropriate drug or sequence of drugs? What is the ideal target? How should tumor response be evaluated? Are financial resources sufficient to treat patients? How do we design trials with these molecules? These are emerging as current dilemmas for clinical oncologists.

Petrelli, F., Cabiddu, M., Cazzaniga, M., Cremonesi, M., & Barni, S. (2008). Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. THE ONCOLOGIST, 13(4), 373-381 [10.1634/theoncologist.2007-0173].

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era

Cazzaniga M;
2008

Abstract

Targeted therapies for breast cancer are evolving rapidly. Trastuzumab has revolutionized breast cancer treatment and outcome, reducing the risk for recurrence and significantly increasing survival, at least for a subgroup of patients. Other targeted therapies, such as bevacizumab, a monoclonal antibody targeting angiogenesis, lapatinib, a dual human epidermal growth factor receptor (HER)-1 and HER-2 inhibitor, other small-molecule tyrosine kinase inhibitors, and mammalian target of rapamycin inhibitors, have been developed in phase II and III clinical trials. Although there has been rapid approval of these new drugs by health authorities, some questions have emerged about their application in clinical practice. What is the appropriate drug or sequence of drugs? What is the ideal target? How should tumor response be evaluated? Are financial resources sufficient to treat patients? How do we design trials with these molecules? These are emerging as current dilemmas for clinical oncologists.
No
Articolo in rivista - Review Essay
Scientifica
breast cancer;
English
373
381
9
Petrelli, F., Cabiddu, M., Cazzaniga, M., Cremonesi, M., & Barni, S. (2008). Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. THE ONCOLOGIST, 13(4), 373-381 [10.1634/theoncologist.2007-0173].
Petrelli, F; Cabiddu, M; Cazzaniga, M; Cremonesi, M; Barni, S
File in questo prodotto:
File Dimensione Formato  
petrelli oncologist 2008.pdf

Solo gestori archivio

Dimensione 5.93 kB
Formato Adobe PDF
5.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/301410
Citazioni
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 24
Social impact